Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

S. Sugawara; J.-S. Lee; J.-H. Kang; H.R. Kim; N. Inui; T. Hida; K.H. Lee; T. Yoshida; H. Tanaka; C.-T. Yang; M. Nishio; Y. Ohe; T. Tamura; N. Yamamoto; C.-J. Yu; H. Akamatsu; Y. Namba; N. Sumiyoshi; K. Nakagawa

doi:10.1016/j.annonc.2021.06.004

journal article Open Access Sep 01, 2021

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

S. Sugawara J.-S. Lee J.-H. Kang H.R. Kim N. Inui T. Hida K.H. Lee T. Yoshida H. Tanaka C.-T. Yang M. Nishio Y. Ohe T. Tamura N. Yamamoto

C.-J. Yu H. Akamatsu Y. Namba N. Sumiyoshi K. Nakagawa

Annals of Oncology Vol. 32 No. 9 pp. 1137-1147 · Elsevier BV

View at Publisher Save 10.1016/j.annonc.2021.06.004

Topics

No keywords indexed for this article. Browse by subject →

References

36

[1]

Mok "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial" Lancet (2019) 10.1016/s0140-6736(18)32409-7

[2]

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez-Abreu, Andrew G. Robinson et al.

New England Journal of Medicine 2016 10.1056/nejmoa1606774

[3]

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel et al.

New England Journal of Medicine 2018 10.1056/nejmoa1801005

[4]

Paz-Ares "Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer" N Engl J Med (2018) 10.1056/nejmoa1810865

[5]

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al.

New England Journal of Medicine 2018 10.1056/nejmoa1716948

[6]

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Gordon J. Freeman, Andrew J. Long, Yoshiko Iwai et al.

Journal of Experimental Medicine 2000 10.1084/jem.192.7.1027

[7]

Carter "PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2" Eur J Immunol (2002) 10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9

[8]

Brahmer "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer" N Engl J Med (2015) 10.1056/nejmoa1504627

[9]

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Hossein Borghaei, Luis Paz-Ares, Leora Horn et al.

New England Journal of Medicine 2015 10.1056/nejmoa1507643

[10]

Zitvogel "Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance" Immunity (2013) 10.1016/j.immuni.2013.06.014

[11]

Zhu "CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of Toll-like receptor 4" Scand J Immunol (2011) 10.1111/j.1365-3083.2011.02514.x

[12]

Champiat "Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC" J Thorac Oncol (2014) 10.1097/jto.0000000000000074

[13]

Manegold "The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC" J Thorac Oncol (2017) 10.1016/j.jtho.2016.10.003

[14]

Martino "Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients" Cell Death Discov (2016) 10.1038/cddiscovery.2016.25

[15]

Alfaro "Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes" Br J Cancer (2009) 10.1038/sj.bjc.6604965

[16]

Wada "The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions" Anticancer Res (2009)

[17]

Osada "The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients" Cancer Immunol Immunother (2008) 10.1007/s00262-007-0441-x

[18]

Terme "VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer" Cancer Res (2013) 10.1158/0008-5472.can-12-2325

[19]

Shrimali "Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer" Cancer Res (2010) 10.1158/0008-5472.can-10-0153

[20]

Motz "Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors" Nat Med (2014) 10.1038/nm.3541

[21]

Kanda "Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study" Ann Oncol (2016) 10.1093/annonc/mdw416

[22]

Kanda "Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer" Cancer Sci (2020) 10.1111/cas.14410

[23]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E.A. Eisenhauer, P. Therasse, J. Bogaerts et al.

European Journal of Cancer 2009 10.1016/j.ejca.2008.10.026

[24]

West "Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial" Lancet Oncol (2019) 10.1016/s1470-2045(19)30167-6

[25]

Yang "Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)" J Thorac Oncol (2020) 10.1016/j.jtho.2020.07.014

[26]

Barlesi F, Nishio M, Cobo M, et al. IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Paper presented at the European Society for Medical Oncology Congress. October 19-23, 2018; Munich, Germany. Abstract LBA54. 10.1093/annonc/mdy424.066

[27]

Niho "Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer" Lung Cancer (2012) 10.1016/j.lungcan.2011.12.005

[28]

Zhou "BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer" J Clin Oncol (2015) 10.1200/jco.2014.59.4424

[29]

Koyama R, Udagawa H, Sugiyama E, et al. Randomized phase II study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small cell lung cancer (CLEAR study). Paper presented at the European Society for Medical Oncology Congress. October 19-23, 2018; Munich, Germany. Abstract 1436P. 10.1093/annonc/mdy292.058

[30]

Sandler "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer" N Engl J Med (2006) 10.1056/nejmoa061884

[31]

Soria "Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer" Ann Oncol (2013) 10.1093/annonc/mds590

[32]

Duan "Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis" JAMA Oncol (2020) 10.1001/jamaoncol.2019.5367

[33]

Terme "VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer" Oncoimmunology (2013) 10.4161/onci.25156

[34]

Shin "Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer" Cancer Res Treat (2019) 10.4143/crt.2018.537

[35]

Guo "Variation of programmed death ligand 1 expression after platinum-based neoadjuvant chemotherapy in lung cancer" J Immunother (2019)

[36]

Nishio "Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer" ESMO Open (2016)

Cited By

165

Comparative Survival of First‐Line Immunotherapy Plus Chemotherapy Versus Immunotherapy Monotherapy in Older Adults With Metastatic Non‐Small Cell Lung Cancer: An Emulated Target Trial Approach

Xiangzhong Xue, Matthew Shane Loop · 2026

Pharmacoepidemiology and Drug Safet...

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

Elena Catanzaro, Manuel Beltrán-Visiedo · 2024

Cellular & Molecular Immunology

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer

Juan J. Alburquerque-Bejar, Pablo Navajas-Chocarro · 2023

Cell Reports Medicine

Immunotherapy in NSCLC Patients with Brain Metastases

Silvia Buriolla, Giacomo Pelizzari · 2022

International Journal of Molecular...

Metrics

165

Citations

36

References

Details

Published: Sep 01, 2021
Vol/Issue: 32(9)
Pages: 1137-1147
License: View

Authors

S

S. Sugawara

Department of Materials Science and Engineering; Tokyo Institute of Technology; Tokyo 152-8552; Japan

NTT Interdisciplinary Research Laboratories, 3-9-11, Midori-cho, Musashino-shi, Tokyo 180, Japan

Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro-ku, Tokyo 152-8551, Japan

Cite This Article

S. Sugawara, J.-S. Lee, J.-H. Kang, et al. (2021). Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Annals of Oncology, 32(9), 1137-1147. https://doi.org/10.1016/j.annonc.2021.06.004

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

You May Also Like